With a deep expertise in translational research and clinical immunology, ILTOO Pharma is at the forefront of revolutionizing the treatment of ADs, aiming to provide patients with more effective and sustainable therapies. By leveraging their knowledge of Tregs, they are developing a pipeline of innovative biotherapies that have the potential to transform the lives of millions of people suffering from autoimmune diseases.